Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 93

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Sickle cell disease

Not recruiting

Study on the Effect of Famotidine in Reducing P-selectin Levels in Children with Sickle Cell Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Famotidine
  • Sponsor:Assistance Publique Hopitaux De Paris

Pyruvate kinase deficiency anaemia

Not recruiting

Study on Long-Term Safety of Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Autologous Cd34+ Hematopoietic Stem Cells Transduced Ex Vivo With A Lentiviral Vector Encoding The Codon-Optimized Version Of Pklr Gene
  • Sponsor:Rocket Pharmaceuticals Inc.

Mantle cell lymphoma refractory

Not recruiting

Study of BGB-11417 for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
  • Sponsor:BeOne Medicines AG

Non-small cell lung cancer+3

Not recruiting

Study on Calcium Folinate to Reduce Pemetrexed Side Effects in Patients with Non-Small Cell Lung Cancer, Mesothelioma, or Thymoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amphia Hospital

Anaemia+1

Not recruiting

Study of AG-946 for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AG-946
  • Sponsor:Agios Pharmaceuticals Inc.

Autoimmune haemolytic anaemia+1

Not recruiting

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Incyte Corp.

Plasma cell myeloma refractory

Not recruiting

Study on the Safety and Effectiveness of BCMACP03 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Galapagos

Follicular lymphoma+2

Not recruiting

Study of Mosunetuzumab for Patients with Early Relapse of Follicular Lymphoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Oslo University Hospital HF

Burkitt's lymphoma+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Hairy cell leukaemia

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Hairy Cell Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Mesna
  • Sponsor:Kite Pharma Inc.

Richter's syndrome

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Kite Pharma Inc.

Waldenstrom's macroglobulinaemia+1

Not recruiting

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Kite Pharma Inc.

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.